The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.
Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines / A. Berzi , N. Varga , S. Sattin , P. Antonazzo , M. Biasin , I. Cetin , D. Trabattoni , A. Bernardi , M. Clerici. - In: VIRUSES. - ISSN 1999-4915. - 6:2(2014 Jan 27), pp. 391-403. [10.3390/v6020391]
Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines
A. Berzi
;N. VargaSecondo
;S. Sattin;P. Antonazzo;M. Biasin;I. Cetin;D. Trabattoni;A. BernardiPenultimo
;M. ClericiUltimo
2014
Abstract
The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.File | Dimensione | Formato | |
---|---|---|---|
viruses-06-00391.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.03 MB
Formato
Adobe PDF
|
1.03 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.